[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$ftuzk3iat2FeoB_ERSd8GTTxqC2C0INUu905FwG062es":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":8,"totalEnrollment":9,"activePrograms":10,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":31,"phaseBuckets":47,"rows":54},"AIO-Studien-gGmbH",[4],59,false,6,23475,4,7,[13,16,18,21,23,25,27,29],{"name":14,"count":15},"Colorectal Neoplasms",3,{"name":17,"count":15},"Metastatic Colorectal Cancer",{"name":19,"count":20},"Biliary Tract Cancer",2,{"name":22,"count":20},"Cholangiocarcinoma",{"name":24,"count":20},"Metastatic Pancreatic Cancer",{"name":26,"count":20},"Metastatic Lung Cancer",{"name":28,"count":20},"Lung Adenocarcinoma Metastatic",{"name":30,"count":20},"Large Cell Lung Carcinoma Metastatic",[32,37,42],{"nctId":33,"briefTitle":34,"date":35,"intervention":36},"NCT05212012","D,L-MEthadone and mFOLFOX6 in Treatment of Advanced Colorectal Cancer","2025-12","Maximum tolerated dose, MTD: D,L-methadone hydrochloride",{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT05089916","Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study","2026-03","Osimertinib",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT05118724","Atezolizumab in Patients With MSI-h\u002FMMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin","2027-04","Atezolizumab",[48,49,50,51,52,53],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[55,92,113,137,155,211,233,278,316,338,366,384,409,434,452,470,554,611,660,699,721,743,765,795,813,841,859,883,915,933,961,979,997,1015,1040,1067,1085,1112,1139,1157,1175,1193,1211,1229,1257,1275,1293,1311,1335,1353,1379,1397,1415,1443,1461,1479,1497,1522,1553,1571,1596,1614,1641,1659,1684,1702,1728,1756,1782,1800,1826,1852,1870,1888,1906,1924,1942,1967,1985,2012],{"intervention":46,"totalTrials":20,"cells":56},{"EARLY_PHASE1":57,"PHASE1":60,"PHASE2":62,"PHASE3":86,"PHASE4":88,"NA":90},{"trials":58,"activeCount":59},[],0,{"trials":61,"activeCount":59},[],{"trials":63,"activeCount":85,"soonestReadout":45},[64,76],{"nctId":65,"briefTitle":66,"status":67,"phases":68,"primaryCompletion":69,"completion":70,"start":71,"enrollment":72,"conditions":73,"interventions":75},"NCT04221529","Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide","COMPLETED",[50],"2024-04-12","2025-04-11","2020-01-06",70,[74],"SCLC, Extensive Stage",[46],{"nctId":43,"briefTitle":44,"status":77,"phases":78,"primaryCompletion":45,"completion":45,"start":79,"enrollment":80,"conditions":81,"interventions":83},"ACTIVE_NOT_RECRUITING",[50],"2021-12-10",80,[82],"Colorectal Cancer",[46,84],"IMM-101",1,{"trials":87,"activeCount":59},[],{"trials":89,"activeCount":59},[],{"trials":91,"activeCount":59},[],{"intervention":36,"totalTrials":85,"cells":93},{"EARLY_PHASE1":94,"PHASE1":96,"PHASE2":98,"PHASE3":107,"PHASE4":109,"NA":111},{"trials":95,"activeCount":59},[],{"trials":97,"activeCount":59},[],{"trials":99,"activeCount":85,"soonestReadout":35},[100],{"nctId":33,"briefTitle":34,"status":77,"phases":101,"primaryCompletion":35,"completion":35,"start":102,"enrollment":103,"conditions":104,"interventions":106},[49,50],"2022-02-17",11,[105],"Chemo-refractory Colorectal Carcinoma",[36],{"trials":108,"activeCount":59},[],{"trials":110,"activeCount":59},[],{"trials":112,"activeCount":59},[],{"intervention":41,"totalTrials":85,"cells":114},{"EARLY_PHASE1":115,"PHASE1":117,"PHASE2":119,"PHASE3":131,"PHASE4":133,"NA":135},{"trials":116,"activeCount":59},[],{"trials":118,"activeCount":59},[],{"trials":120,"activeCount":85,"soonestReadout":40},[121],{"nctId":38,"briefTitle":39,"status":77,"phases":122,"primaryCompletion":40,"completion":123,"start":124,"enrollment":125,"conditions":126,"interventions":130},[50],"2027-03","2022-01-20",42,[127,128,129],"NSCLC","EGFR Positive Non-small Cell Lung Cancer","Oligoprogression",[41],{"trials":132,"activeCount":59},[],{"trials":134,"activeCount":59},[],{"trials":136,"activeCount":59},[],{"intervention":84,"totalTrials":85,"cells":138},{"EARLY_PHASE1":139,"PHASE1":141,"PHASE2":143,"PHASE3":149,"PHASE4":151,"NA":153},{"trials":140,"activeCount":59},[],{"trials":142,"activeCount":59},[],{"trials":144,"activeCount":85,"soonestReadout":45},[145],{"nctId":43,"briefTitle":44,"status":77,"phases":146,"primaryCompletion":45,"completion":45,"start":79,"enrollment":80,"conditions":147,"interventions":148},[50],[82],[46,84],{"trials":150,"activeCount":59},[],{"trials":152,"activeCount":59},[],{"trials":154,"activeCount":59},[],{"intervention":156,"totalTrials":15,"cells":157},"Gemcitabine",{"EARLY_PHASE1":158,"PHASE1":160,"PHASE2":162,"PHASE3":193,"PHASE4":195,"NA":209},{"trials":159,"activeCount":59},[],{"trials":161,"activeCount":59},[],{"trials":163,"activeCount":59},[164,179],{"nctId":165,"briefTitle":166,"status":67,"phases":167,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":171,"interventions":175},"NCT03473574","Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine\u002FCisplatin Compared to Gemcitabine\u002FCisplatin in CCA Patients",[50],"2022-03-15","2018-05-02",128,[22,172,173,174],"Gall Bladder Carcinoma","Cholangiocarcinoma Non-resectable","Gallbladder Carcinoma Non-Resectable",[176,156,177,178],"Durvalumab","Cisplatin","Tremelimumab",{"nctId":180,"briefTitle":181,"status":67,"phases":182,"primaryCompletion":183,"completion":183,"start":184,"enrollment":185,"conditions":186,"interventions":189},"NCT03345810","Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)",[50],"2022-12-31","2017-12-14",200,[187,26,188,28,30],"Carcinoma, Non-Small-Cell Lung","Non Small Cell Lung Cancer",[176,190,156,191,192],"Vinorelbine","nab-Paclitaxel","Carboplatin",{"trials":194,"activeCount":59},[],{"trials":196,"activeCount":59},[197],{"nctId":198,"briefTitle":199,"status":67,"phases":200,"primaryCompletion":201,"completion":202,"start":203,"enrollment":204,"conditions":205,"interventions":207},"NCT02812992","Geriatric Assessment Directed Trial to Evaluate Gemcitabine +\u002F- Nab-paclitaxel in Elderly Pancreatic Cancer Patients",[52],"2020-02","2021-02","2016-06",32,[206],"Adenocarcinoma Pancreas",[208,156],"Nab-paclitaxel",{"trials":210,"activeCount":59},[],{"intervention":208,"totalTrials":20,"cells":212},{"EARLY_PHASE1":213,"PHASE1":215,"PHASE2":217,"PHASE3":223,"PHASE4":225,"NA":231},{"trials":214,"activeCount":59},[],{"trials":216,"activeCount":59},[],{"trials":218,"activeCount":59},[219],{"nctId":180,"briefTitle":181,"status":67,"phases":220,"primaryCompletion":183,"completion":183,"start":184,"enrollment":185,"conditions":221,"interventions":222},[50],[187,26,188,28,30],[176,190,156,191,192],{"trials":224,"activeCount":59},[],{"trials":226,"activeCount":59},[227],{"nctId":198,"briefTitle":199,"status":67,"phases":228,"primaryCompletion":201,"completion":202,"start":203,"enrollment":204,"conditions":229,"interventions":230},[52],[206],[208,156],{"trials":232,"activeCount":59},[],{"intervention":234,"totalTrials":20,"cells":235},"Docetaxel",{"EARLY_PHASE1":236,"PHASE1":238,"PHASE2":240,"PHASE3":255,"PHASE4":274,"NA":276},{"trials":237,"activeCount":59},[],{"trials":239,"activeCount":59},[],{"trials":241,"activeCount":59},[242],{"nctId":243,"briefTitle":244,"status":67,"phases":245,"primaryCompletion":246,"completion":247,"start":248,"enrollment":249,"conditions":250,"interventions":253},"NCT03620123","A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck",[50],"2021-06-20","2022-06-19","2018-07-16",54,[251,252],"Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","Carcinoma, Squamous Cell of Head and Neck",[254,234],"Nivolumab and Ipilimumab",{"trials":256,"activeCount":59},[257],{"nctId":258,"briefTitle":259,"status":260,"phases":261,"primaryCompletion":262,"completion":263,"start":264,"enrollment":85,"conditions":265,"interventions":270},"NCT02326285","Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB","TERMINATED",[50,51],"2017-03-28","2018-01","2015-11",[266,267,268,269,127],"Non-squamous Non-small Cell Lung Cancer Stage II","Non-squamous Non-small Cell Lung Cancer Stage IIIA","Non-squamous Non-small Cell Lung Cancer Stage IIIB","Activating EGFR Mutation",[271,272,273],"Gefitinib","docetaxel","cisplatin",{"trials":275,"activeCount":59},[],{"trials":277,"activeCount":59},[],{"intervention":279,"totalTrials":20,"cells":280},"Panitumumab",{"EARLY_PHASE1":281,"PHASE1":283,"PHASE2":285,"PHASE3":298,"PHASE4":312,"NA":314},{"trials":282,"activeCount":59},[],{"trials":284,"activeCount":59},[],{"trials":286,"activeCount":59},[287],{"nctId":288,"briefTitle":289,"status":67,"phases":290,"primaryCompletion":291,"completion":291,"start":292,"enrollment":293,"conditions":294,"interventions":295},"NCT01991873","Maintenance Therapy With 5-FU\u002FFA Plus Panitumumab vs. 5-FU\u002FFA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer",[50],"2023-02-18","2014-04",387,[17],[296,279,297,279],"Maintenance Chemotherapy","mFOLFOX6",{"trials":299,"activeCount":59},[300],{"nctId":301,"briefTitle":302,"status":260,"phases":303,"primaryCompletion":304,"completion":305,"start":306,"enrollment":307,"conditions":308,"interventions":310},"NCT01627379","Cisplatin and 5-FU +\u002F- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer",[51],"2015-05","2017-05","2012-05",300,[309],"Esophageal Squamous Cell Cancer",[311,279],"Cisplatin, 5-FU",{"trials":313,"activeCount":59},[],{"trials":315,"activeCount":59},[],{"intervention":177,"totalTrials":20,"cells":317},{"EARLY_PHASE1":318,"PHASE1":320,"PHASE2":322,"PHASE3":328,"PHASE4":334,"NA":336},{"trials":319,"activeCount":59},[],{"trials":321,"activeCount":59},[],{"trials":323,"activeCount":59},[324],{"nctId":165,"briefTitle":166,"status":67,"phases":325,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":326,"interventions":327},[50],[22,172,173,174],[176,156,177,178],{"trials":329,"activeCount":59},[330],{"nctId":258,"briefTitle":259,"status":260,"phases":331,"primaryCompletion":262,"completion":263,"start":264,"enrollment":85,"conditions":332,"interventions":333},[50,51],[266,267,268,269,127],[271,272,273],{"trials":335,"activeCount":59},[],{"trials":337,"activeCount":59},[],{"intervention":339,"totalTrials":85,"cells":340},"Rivaroxaban",{"EARLY_PHASE1":341,"PHASE1":343,"PHASE2":345,"PHASE3":347,"PHASE4":362,"NA":364},{"trials":342,"activeCount":59},[],{"trials":344,"activeCount":59},[],{"trials":346,"activeCount":59},[],{"trials":348,"activeCount":59},[349],{"nctId":350,"briefTitle":351,"status":260,"phases":352,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":357,"interventions":360},"NCT02583191","Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients",[51],"2019-06-11","2019-08-19","2016-03-23",246,[358,359],"Venous Thromboembolism","Cancer",[339,361],"low-molecular heparine",{"trials":363,"activeCount":59},[],{"trials":365,"activeCount":59},[],{"intervention":361,"totalTrials":85,"cells":367},{"EARLY_PHASE1":368,"PHASE1":370,"PHASE2":372,"PHASE3":374,"PHASE4":380,"NA":382},{"trials":369,"activeCount":59},[],{"trials":371,"activeCount":59},[],{"trials":373,"activeCount":59},[],{"trials":375,"activeCount":59},[376],{"nctId":350,"briefTitle":351,"status":260,"phases":377,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":378,"interventions":379},[51],[358,359],[339,361],{"trials":381,"activeCount":59},[],{"trials":383,"activeCount":59},[],{"intervention":385,"totalTrials":85,"cells":386},"Irinotecan Liposomal Injection [Onivyde]",{"EARLY_PHASE1":387,"PHASE1":389,"PHASE2":391,"PHASE3":393,"PHASE4":405,"NA":407},{"trials":388,"activeCount":59},[],{"trials":390,"activeCount":59},[],{"trials":392,"activeCount":59},[],{"trials":394,"activeCount":59},[395],{"nctId":396,"briefTitle":397,"status":67,"phases":398,"primaryCompletion":399,"completion":399,"start":400,"enrollment":401,"conditions":402,"interventions":404},"NCT03468335","2nd-line Therapy With Nal-IRI After Gem\u002FNab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy",[51],"2022-05-31","2018-03-31",151,[403,24],"Locally Advanced Pancreatic Cancer",[385],{"trials":406,"activeCount":59},[],{"trials":408,"activeCount":59},[],{"intervention":410,"totalTrials":85,"cells":411},"5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab",{"EARLY_PHASE1":412,"PHASE1":414,"PHASE2":416,"PHASE3":418,"PHASE4":430,"NA":432},{"trials":413,"activeCount":59},[],{"trials":415,"activeCount":59},[],{"trials":417,"activeCount":59},[],{"trials":419,"activeCount":59},[420],{"nctId":421,"briefTitle":422,"status":67,"phases":423,"primaryCompletion":424,"completion":425,"start":426,"enrollment":427,"conditions":428,"interventions":429},"NCT00973609","Optimal Maintenance Therapy With Bevacizumab After Induction in Metastatic Colorectal Cancer (CRC)",[51],"2014-12","2015-08","2009-08",853,[14],[410,410,410],{"trials":431,"activeCount":59},[],{"trials":433,"activeCount":59},[],{"intervention":271,"totalTrials":85,"cells":435},{"EARLY_PHASE1":436,"PHASE1":438,"PHASE2":440,"PHASE3":442,"PHASE4":448,"NA":450},{"trials":437,"activeCount":59},[],{"trials":439,"activeCount":59},[],{"trials":441,"activeCount":59},[],{"trials":443,"activeCount":59},[444],{"nctId":258,"briefTitle":259,"status":260,"phases":445,"primaryCompletion":262,"completion":263,"start":264,"enrollment":85,"conditions":446,"interventions":447},[50,51],[266,267,268,269,127],[271,272,273],{"trials":449,"activeCount":59},[],{"trials":451,"activeCount":59},[],{"intervention":311,"totalTrials":85,"cells":453},{"EARLY_PHASE1":454,"PHASE1":456,"PHASE2":458,"PHASE3":460,"PHASE4":466,"NA":468},{"trials":455,"activeCount":59},[],{"trials":457,"activeCount":59},[],{"trials":459,"activeCount":59},[],{"trials":461,"activeCount":59},[462],{"nctId":301,"briefTitle":302,"status":260,"phases":463,"primaryCompletion":304,"completion":305,"start":306,"enrollment":307,"conditions":464,"interventions":465},[51],[309],[311,279],{"trials":467,"activeCount":59},[],{"trials":469,"activeCount":59},[],{"intervention":471,"totalTrials":472,"cells":473},"Nivolumab",5,{"EARLY_PHASE1":474,"PHASE1":476,"PHASE2":478,"PHASE3":548,"PHASE4":550,"NA":552},{"trials":475,"activeCount":59},[],{"trials":477,"activeCount":59},[],{"trials":479,"activeCount":59},[480,493,505,523,535],{"nctId":481,"briefTitle":482,"status":67,"phases":483,"primaryCompletion":484,"completion":79,"start":485,"enrollment":486,"conditions":487,"interventions":491},"NCT03572582","Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma",[50],"2021-10-12","2018-06-14",49,[488,489,490],"Carcinoma, Hepatocellular","Hepatic Carcinoma","Hepatocellular Cancer",[471,492],"TACE",{"nctId":494,"briefTitle":495,"status":67,"phases":496,"primaryCompletion":497,"completion":497,"start":498,"enrollment":499,"conditions":500,"interventions":503},"NCT03044626","Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC",[50],"2020-12-31","2017-02-10",101,[501,26,502,28,30],"Carcinoma，Non-Small-Cell Lung","Nonsmall Cell Lung Cancer",[504,471],"Radiotherapy",{"nctId":506,"briefTitle":507,"status":67,"phases":508,"primaryCompletion":509,"completion":509,"start":510,"enrollment":511,"conditions":512,"interventions":521},"NCT03416244","A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer",[50],"2021-11-19","2018-02-21",66,[513,514,515,516,517,518,519,520],"Esophageal Cancer","Oesophageal Cancer","Oesophageal Cancer Metastatic","Esophageal Cancer Metastatic","Esophageal Cancers NOS","Oesophageal Cancer Nos","GastroEsophageal Cancer","Gastrooesophageal Cancer",[471,522],"Ipilimumab",{"nctId":524,"briefTitle":525,"status":260,"phases":526,"primaryCompletion":527,"completion":528,"start":529,"enrollment":486,"conditions":530,"interventions":532},"NCT02959554","Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control",[50],"2020-08","2021-01","2016-12",[531],"Metastatic Renal Cell Carcinoma",[471,533,534],"Sunitinib","Pazopanib",{"nctId":536,"briefTitle":537,"status":67,"phases":538,"primaryCompletion":539,"completion":539,"start":540,"enrollment":541,"conditions":542,"interventions":547},"NCT03409848","Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma",[50],"2022-03-05","2018-03-01",97,[543,513,544,545,546,519],"Gastric Cancer","Adenocarcinoma Gastric","HER2 Positive Gastric Cancer","Metastatic Gastric Cancer",[471,471,522],{"trials":549,"activeCount":59},[],{"trials":551,"activeCount":59},[],{"trials":553,"activeCount":59},[],{"intervention":555,"totalTrials":15,"cells":556},"Leucovorin",{"EARLY_PHASE1":557,"PHASE1":559,"PHASE2":561,"PHASE3":605,"PHASE4":607,"NA":609},{"trials":558,"activeCount":59},[],{"trials":560,"activeCount":59},[],{"trials":562,"activeCount":59},[563,579,593],{"nctId":564,"briefTitle":565,"status":67,"phases":566,"primaryCompletion":567,"completion":568,"start":569,"enrollment":570,"conditions":571,"interventions":575},"NCT03043547","Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies",[50],"2021-12-08","2022-03-08","2017-10-24",100,[173,572,573,574],"Cholangiocarcinoma Metastatic","Cholangiocarcinoma of the Gallbladder","Cholangiocarcinoma Advanced",[576,577,578],"nal-IRI","5-FU","leucovorin",{"nctId":580,"briefTitle":581,"status":67,"phases":582,"primaryCompletion":583,"completion":584,"start":585,"enrollment":586,"conditions":587,"interventions":590},"NCT03043729","mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer",[50],"2021-01-11","2022-06-01","2017-03-06",119,[588,589],"Rectal Cancer","Rectosigmoid Cancer",[591,577,555,592],"Oxaliplatin","Aflibercept",{"nctId":594,"briefTitle":595,"status":260,"phases":596,"primaryCompletion":597,"completion":598,"start":599,"enrollment":499,"conditions":600,"interventions":601},"NCT00889343","Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer",[50],"2011-11","2012-12","2009-03",[14],[602,603,555,604],"Sorafenib","Oxaliplatin or Irinotecan","5-Fluorouracil",{"trials":606,"activeCount":59},[],{"trials":608,"activeCount":59},[],{"trials":610,"activeCount":59},[],{"intervention":612,"totalTrials":15,"cells":613},"Pembrolizumab",{"EARLY_PHASE1":614,"PHASE1":616,"PHASE2":618,"PHASE3":654,"PHASE4":656,"NA":658},{"trials":615,"activeCount":59},[],{"trials":617,"activeCount":59},[],{"trials":619,"activeCount":59},[620,632,643],{"nctId":621,"briefTitle":622,"status":260,"phases":623,"primaryCompletion":624,"completion":625,"start":626,"enrollment":627,"conditions":628,"interventions":630},"NCT03193931","Study Comparing Pembrolizumab With Methotrexate in Elderly, Frail or Cisplatin-ineligible Patients With Head and Neck Cancers",[50],"2021-11-24","2022-03-23","2018-02-02",47,[629],"Cancer of Head and Neck",[612,631],"Methotrexate Injectable Solution",{"nctId":633,"briefTitle":634,"status":67,"phases":635,"primaryCompletion":636,"completion":637,"start":638,"enrollment":639,"conditions":640,"interventions":642},"NCT03197467","Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer",[50],"2021-10-30","2023-05-05","2018-06-18",30,[641],"Non-small Cell Lung Cancer (NSCLC)",[612],{"nctId":644,"briefTitle":645,"status":260,"phases":646,"primaryCompletion":647,"completion":648,"start":649,"enrollment":650,"conditions":651,"interventions":653},"NCT02564380","Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients With Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC)",[50],"2020-05-23","2020-11-23","2016-01-19",41,[652],"Metastatic Squamous Non-small Cell Lung Cancer",[612],{"trials":655,"activeCount":59},[],{"trials":657,"activeCount":59},[],{"trials":659,"activeCount":59},[],{"intervention":661,"totalTrials":20,"cells":662},"Nivolumab\u002FIpilimumab",{"EARLY_PHASE1":663,"PHASE1":665,"PHASE2":667,"PHASE3":693,"PHASE4":695,"NA":697},{"trials":664,"activeCount":59},[],{"trials":666,"activeCount":59},[],{"trials":668,"activeCount":59},[669,682],{"nctId":670,"briefTitle":671,"status":672,"phases":673,"primaryCompletion":674,"completion":291,"start":675,"enrollment":676,"conditions":677,"interventions":681},"NCT03219775","Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma","UNKNOWN",[50],"2021-09-16","2017-07-06",169,[678,679,680],"Transitional Cell Carcinoma","Advanced Cancer","Metastatic Cancer",[661],{"nctId":683,"briefTitle":684,"status":67,"phases":685,"primaryCompletion":686,"completion":687,"start":688,"enrollment":185,"conditions":689,"interventions":692},"NCT02917772","Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma",[50],"2021-10","2022-10","2016-10",[690,691],"Carcinoma, Renal Cell","Clear-cell Metastatic Renal Cell Carcinoma",[661],{"trials":694,"activeCount":59},[],{"trials":696,"activeCount":59},[],{"trials":698,"activeCount":59},[],{"intervention":577,"totalTrials":20,"cells":700},{"EARLY_PHASE1":701,"PHASE1":703,"PHASE2":705,"PHASE3":715,"PHASE4":717,"NA":719},{"trials":702,"activeCount":59},[],{"trials":704,"activeCount":59},[],{"trials":706,"activeCount":59},[707,711],{"nctId":564,"briefTitle":565,"status":67,"phases":708,"primaryCompletion":567,"completion":568,"start":569,"enrollment":570,"conditions":709,"interventions":710},[50],[173,572,573,574],[576,577,578],{"nctId":580,"briefTitle":581,"status":67,"phases":712,"primaryCompletion":583,"completion":584,"start":585,"enrollment":586,"conditions":713,"interventions":714},[50],[588,589],[591,577,555,592],{"trials":716,"activeCount":59},[],{"trials":718,"activeCount":59},[],{"trials":720,"activeCount":59},[],{"intervention":522,"totalTrials":20,"cells":722},{"EARLY_PHASE1":723,"PHASE1":725,"PHASE2":727,"PHASE3":737,"PHASE4":739,"NA":741},{"trials":724,"activeCount":59},[],{"trials":726,"activeCount":59},[],{"trials":728,"activeCount":59},[729,733],{"nctId":506,"briefTitle":507,"status":67,"phases":730,"primaryCompletion":509,"completion":509,"start":510,"enrollment":511,"conditions":731,"interventions":732},[50],[513,514,515,516,517,518,519,520],[471,522],{"nctId":536,"briefTitle":537,"status":67,"phases":734,"primaryCompletion":539,"completion":539,"start":540,"enrollment":541,"conditions":735,"interventions":736},[50],[543,513,544,545,546,519],[471,471,522],{"trials":738,"activeCount":59},[],{"trials":740,"activeCount":59},[],{"trials":742,"activeCount":59},[],{"intervention":176,"totalTrials":20,"cells":744},{"EARLY_PHASE1":745,"PHASE1":747,"PHASE2":749,"PHASE3":759,"PHASE4":761,"NA":763},{"trials":746,"activeCount":59},[],{"trials":748,"activeCount":59},[],{"trials":750,"activeCount":59},[751,755],{"nctId":165,"briefTitle":166,"status":67,"phases":752,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":753,"interventions":754},[50],[22,172,173,174],[176,156,177,178],{"nctId":180,"briefTitle":181,"status":67,"phases":756,"primaryCompletion":183,"completion":183,"start":184,"enrollment":185,"conditions":757,"interventions":758},[50],[187,26,188,28,30],[176,190,156,191,192],{"trials":760,"activeCount":59},[],{"trials":762,"activeCount":59},[],{"trials":764,"activeCount":59},[],{"intervention":190,"totalTrials":20,"cells":766},{"EARLY_PHASE1":767,"PHASE1":769,"PHASE2":771,"PHASE3":789,"PHASE4":791,"NA":793},{"trials":768,"activeCount":59},[],{"trials":770,"activeCount":59},[],{"trials":772,"activeCount":59},[773,785],{"nctId":774,"briefTitle":775,"status":67,"phases":776,"primaryCompletion":777,"completion":777,"start":778,"enrollment":779,"conditions":780,"interventions":783},"NCT01520103","Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer",[50],"2016-10-31","2012-01",139,[781,782],"Her2-negative Metastatic Breast Cancer","Her2-negative Locally Advanced Breast Cancer",[784,190],"Vinorebine, Everolimus",{"nctId":180,"briefTitle":181,"status":67,"phases":786,"primaryCompletion":183,"completion":183,"start":184,"enrollment":185,"conditions":787,"interventions":788},[50],[187,26,188,28,30],[176,190,156,191,192],{"trials":790,"activeCount":59},[],{"trials":792,"activeCount":59},[],{"trials":794,"activeCount":59},[],{"intervention":492,"totalTrials":85,"cells":796},{"EARLY_PHASE1":797,"PHASE1":799,"PHASE2":801,"PHASE3":807,"PHASE4":809,"NA":811},{"trials":798,"activeCount":59},[],{"trials":800,"activeCount":59},[],{"trials":802,"activeCount":59},[803],{"nctId":481,"briefTitle":482,"status":67,"phases":804,"primaryCompletion":484,"completion":79,"start":485,"enrollment":486,"conditions":805,"interventions":806},[50],[488,489,490],[471,492],{"trials":808,"activeCount":59},[],{"trials":810,"activeCount":59},[],{"trials":812,"activeCount":59},[],{"intervention":814,"totalTrials":85,"cells":815},"5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab",{"EARLY_PHASE1":816,"PHASE1":818,"PHASE2":820,"PHASE3":835,"PHASE4":837,"NA":839},{"trials":817,"activeCount":59},[],{"trials":819,"activeCount":59},[],{"trials":821,"activeCount":59},[822],{"nctId":823,"briefTitle":824,"status":67,"phases":825,"primaryCompletion":826,"completion":827,"start":828,"enrollment":829,"conditions":830,"interventions":833},"NCT01472029","Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach",[50],"2014-08-25","2016-09-12","2011-12",53,[831,832],"Adenocarcinoma of the Gastroesophageal Junction","Adenocarcinoma of the Stomach",[814,834],"Post-operative treatment trastuzumab mono therapy",{"trials":836,"activeCount":59},[],{"trials":838,"activeCount":59},[],{"trials":840,"activeCount":59},[],{"intervention":834,"totalTrials":85,"cells":842},{"EARLY_PHASE1":843,"PHASE1":845,"PHASE2":847,"PHASE3":853,"PHASE4":855,"NA":857},{"trials":844,"activeCount":59},[],{"trials":846,"activeCount":59},[],{"trials":848,"activeCount":59},[849],{"nctId":823,"briefTitle":824,"status":67,"phases":850,"primaryCompletion":826,"completion":827,"start":828,"enrollment":829,"conditions":851,"interventions":852},[50],[831,832],[814,834],{"trials":854,"activeCount":59},[],{"trials":856,"activeCount":59},[],{"trials":858,"activeCount":59},[],{"intervention":860,"totalTrials":85,"cells":861},"Bintrafusp alfa",{"EARLY_PHASE1":862,"PHASE1":864,"PHASE2":866,"PHASE3":877,"PHASE4":879,"NA":881},{"trials":863,"activeCount":59},[],{"trials":865,"activeCount":59},[],{"trials":867,"activeCount":59},[868],{"nctId":869,"briefTitle":870,"status":260,"phases":871,"primaryCompletion":872,"completion":873,"start":874,"enrollment":15,"conditions":875,"interventions":876},"NCT04727541","Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer",[50],"2021-10-04","2022-01-05","2021-07-08",[19,22],[860],{"trials":878,"activeCount":59},[],{"trials":880,"activeCount":59},[],{"trials":882,"activeCount":59},[],{"intervention":884,"totalTrials":85,"cells":885},"Arm NaI-IRI + 5-FU + Leucovorin",{"EARLY_PHASE1":886,"PHASE1":888,"PHASE2":890,"PHASE3":909,"PHASE4":911,"NA":913},{"trials":887,"activeCount":59},[],{"trials":889,"activeCount":59},[],{"trials":891,"activeCount":59},[892],{"nctId":893,"briefTitle":894,"status":67,"phases":895,"primaryCompletion":896,"completion":897,"start":898,"enrollment":899,"conditions":900,"interventions":907},"NCT03044587","Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer",[50],"2022-01-01","2025-01-31","2018-01-24",93,[901,19,902,903,904,905,906],"Adenocarcinoma Metastatic","Adenocarcinoma of the Biliary Tract","Adenocarinoma Locally Advanced","Non-Resectable Hepatocellular Carcinoma","Intrahepatic Bile Duct Carcinoma","Extrahepatic Bile Duct Carcinoma",[884,908],"Arm Cisplatin + Gemcitabine",{"trials":910,"activeCount":59},[],{"trials":912,"activeCount":59},[],{"trials":914,"activeCount":59},[],{"intervention":908,"totalTrials":85,"cells":916},{"EARLY_PHASE1":917,"PHASE1":919,"PHASE2":921,"PHASE3":927,"PHASE4":929,"NA":931},{"trials":918,"activeCount":59},[],{"trials":920,"activeCount":59},[],{"trials":922,"activeCount":59},[923],{"nctId":893,"briefTitle":894,"status":67,"phases":924,"primaryCompletion":896,"completion":897,"start":898,"enrollment":899,"conditions":925,"interventions":926},[50],[901,19,902,903,904,905,906],[884,908],{"trials":928,"activeCount":59},[],{"trials":930,"activeCount":59},[],{"trials":932,"activeCount":59},[],{"intervention":934,"totalTrials":85,"cells":935},"Cabazitaxel",{"EARLY_PHASE1":936,"PHASE1":938,"PHASE2":940,"PHASE3":955,"PHASE4":957,"NA":959},{"trials":937,"activeCount":59},[],{"trials":939,"activeCount":59},[],{"trials":941,"activeCount":59},[942],{"nctId":943,"briefTitle":944,"status":260,"phases":945,"primaryCompletion":946,"completion":947,"start":425,"enrollment":948,"conditions":949,"interventions":954},"NCT02166658","A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet)",[50],"2017-04","2018-01-18",8,[950,951,952,953],"Breast Cancer","Lung Cancer","Recurrent Brain Metastases","Progressive Brain Metastases",[934],{"trials":956,"activeCount":59},[],{"trials":958,"activeCount":59},[],{"trials":960,"activeCount":59},[],{"intervention":504,"totalTrials":85,"cells":962},{"EARLY_PHASE1":963,"PHASE1":965,"PHASE2":967,"PHASE3":973,"PHASE4":975,"NA":977},{"trials":964,"activeCount":59},[],{"trials":966,"activeCount":59},[],{"trials":968,"activeCount":59},[969],{"nctId":494,"briefTitle":495,"status":67,"phases":970,"primaryCompletion":497,"completion":497,"start":498,"enrollment":499,"conditions":971,"interventions":972},[50],[501,26,502,28,30],[504,471],{"trials":974,"activeCount":59},[],{"trials":976,"activeCount":59},[],{"trials":978,"activeCount":59},[],{"intervention":254,"totalTrials":85,"cells":980},{"EARLY_PHASE1":981,"PHASE1":983,"PHASE2":985,"PHASE3":991,"PHASE4":993,"NA":995},{"trials":982,"activeCount":59},[],{"trials":984,"activeCount":59},[],{"trials":986,"activeCount":59},[987],{"nctId":243,"briefTitle":244,"status":67,"phases":988,"primaryCompletion":246,"completion":247,"start":248,"enrollment":249,"conditions":989,"interventions":990},[50],[251,252],[254,234],{"trials":992,"activeCount":59},[],{"trials":994,"activeCount":59},[],{"trials":996,"activeCount":59},[],{"intervention":576,"totalTrials":85,"cells":998},{"EARLY_PHASE1":999,"PHASE1":1001,"PHASE2":1003,"PHASE3":1009,"PHASE4":1011,"NA":1013},{"trials":1000,"activeCount":59},[],{"trials":1002,"activeCount":59},[],{"trials":1004,"activeCount":59},[1005],{"nctId":564,"briefTitle":565,"status":67,"phases":1006,"primaryCompletion":567,"completion":568,"start":569,"enrollment":570,"conditions":1007,"interventions":1008},[50],[173,572,573,574],[576,577,578],{"trials":1010,"activeCount":59},[],{"trials":1012,"activeCount":59},[],{"trials":1014,"activeCount":59},[],{"intervention":1016,"totalTrials":85,"cells":1017},"Bevacizumab",{"EARLY_PHASE1":1018,"PHASE1":1020,"PHASE2":1022,"PHASE3":1034,"PHASE4":1036,"NA":1038},{"trials":1019,"activeCount":59},[],{"trials":1021,"activeCount":59},[],{"trials":1023,"activeCount":59},[1024],{"nctId":1025,"briefTitle":1026,"status":67,"phases":1027,"primaryCompletion":1028,"completion":424,"start":1029,"enrollment":829,"conditions":1030,"interventions":1033},"NCT01200121","Bevacizumab as a Palliative Treatment for Patients With Symptomatic Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers",[50],"2014-08","2010-02",[1031,1032],"Malignant Ascites","Gastrointestinal Cancers",[1016],{"trials":1035,"activeCount":59},[],{"trials":1037,"activeCount":59},[],{"trials":1039,"activeCount":59},[],{"intervention":1041,"totalTrials":85,"cells":1042},"perioperative nab-paclitaxel\u002Fgemcitabine",{"EARLY_PHASE1":1043,"PHASE1":1045,"PHASE2":1047,"PHASE3":1061,"PHASE4":1063,"NA":1065},{"trials":1044,"activeCount":59},[],{"trials":1046,"activeCount":59},[],{"trials":1048,"activeCount":59},[1049],{"nctId":1050,"briefTitle":1051,"status":67,"phases":1052,"primaryCompletion":1053,"completion":687,"start":1054,"enrollment":1055,"conditions":1056,"interventions":1059},"NCT02047513","Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer",[50],"2021-04","2015-07",127,[1057,1058],"Resectable Pancreatic Cancer","Ductal Adenocarcinoma of the Pancreas",[1041,1060],"adjuvant nab-paclitaxel\u002Fgemcitabine",{"trials":1062,"activeCount":59},[],{"trials":1064,"activeCount":59},[],{"trials":1066,"activeCount":59},[],{"intervention":1060,"totalTrials":85,"cells":1068},{"EARLY_PHASE1":1069,"PHASE1":1071,"PHASE2":1073,"PHASE3":1079,"PHASE4":1081,"NA":1083},{"trials":1070,"activeCount":59},[],{"trials":1072,"activeCount":59},[],{"trials":1074,"activeCount":59},[1075],{"nctId":1050,"briefTitle":1051,"status":67,"phases":1076,"primaryCompletion":1053,"completion":687,"start":1054,"enrollment":1055,"conditions":1077,"interventions":1078},[50],[1057,1058],[1041,1060],{"trials":1080,"activeCount":59},[],{"trials":1082,"activeCount":59},[],{"trials":1084,"activeCount":59},[],{"intervention":1086,"totalTrials":85,"cells":1087},"Binimetinib",{"EARLY_PHASE1":1088,"PHASE1":1090,"PHASE2":1092,"PHASE3":1106,"PHASE4":1108,"NA":1110},{"trials":1089,"activeCount":59},[],{"trials":1091,"activeCount":59},[],{"trials":1093,"activeCount":59},[1094],{"nctId":1095,"briefTitle":1096,"status":67,"phases":1097,"primaryCompletion":1098,"completion":897,"start":1099,"enrollment":20,"conditions":1100,"interventions":1105},"NCT05510895","Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated\u002FpMMR Localized Colorectal Cancer",[50],"2024-07-31","2022-09-01",[82,1101,1102,1103,1104],"Colon Cancer","BRAF V600E","BRAF V600 Mutation","Localized Cancer",[1086],{"trials":1107,"activeCount":59},[],{"trials":1109,"activeCount":59},[],{"trials":1111,"activeCount":59},[],{"intervention":1113,"totalTrials":85,"cells":1114},"Erythromycin",{"EARLY_PHASE1":1115,"PHASE1":1117,"PHASE2":1119,"PHASE3":1133,"PHASE4":1135,"NA":1137},{"trials":1116,"activeCount":59},[],{"trials":1118,"activeCount":59},[],{"trials":1120,"activeCount":59},[1121],{"nctId":1122,"briefTitle":1123,"status":67,"phases":1124,"primaryCompletion":1125,"completion":1126,"start":1127,"enrollment":1128,"conditions":1129,"interventions":1131},"NCT01668498","Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of QoL in Patient With Ras-wt Colorectal Cancer",[50],"2015-01","2016-03","2011-05",88,[1130],"Ras-wildtype Colorectal Cancer",[1113,1132],"Doxycycline",{"trials":1134,"activeCount":59},[],{"trials":1136,"activeCount":59},[],{"trials":1138,"activeCount":59},[],{"intervention":1132,"totalTrials":85,"cells":1140},{"EARLY_PHASE1":1141,"PHASE1":1143,"PHASE2":1145,"PHASE3":1151,"PHASE4":1153,"NA":1155},{"trials":1142,"activeCount":59},[],{"trials":1144,"activeCount":59},[],{"trials":1146,"activeCount":59},[1147],{"nctId":1122,"briefTitle":1123,"status":67,"phases":1148,"primaryCompletion":1125,"completion":1126,"start":1127,"enrollment":1128,"conditions":1149,"interventions":1150},[50],[1130],[1113,1132],{"trials":1152,"activeCount":59},[],{"trials":1154,"activeCount":59},[],{"trials":1156,"activeCount":59},[],{"intervention":533,"totalTrials":85,"cells":1158},{"EARLY_PHASE1":1159,"PHASE1":1161,"PHASE2":1163,"PHASE3":1169,"PHASE4":1171,"NA":1173},{"trials":1160,"activeCount":59},[],{"trials":1162,"activeCount":59},[],{"trials":1164,"activeCount":59},[1165],{"nctId":524,"briefTitle":525,"status":260,"phases":1166,"primaryCompletion":527,"completion":528,"start":529,"enrollment":486,"conditions":1167,"interventions":1168},[50],[531],[471,533,534],{"trials":1170,"activeCount":59},[],{"trials":1172,"activeCount":59},[],{"trials":1174,"activeCount":59},[],{"intervention":534,"totalTrials":85,"cells":1176},{"EARLY_PHASE1":1177,"PHASE1":1179,"PHASE2":1181,"PHASE3":1187,"PHASE4":1189,"NA":1191},{"trials":1178,"activeCount":59},[],{"trials":1180,"activeCount":59},[],{"trials":1182,"activeCount":59},[1183],{"nctId":524,"briefTitle":525,"status":260,"phases":1184,"primaryCompletion":527,"completion":528,"start":529,"enrollment":486,"conditions":1185,"interventions":1186},[50],[531],[471,533,534],{"trials":1188,"activeCount":59},[],{"trials":1190,"activeCount":59},[],{"trials":1192,"activeCount":59},[],{"intervention":591,"totalTrials":85,"cells":1194},{"EARLY_PHASE1":1195,"PHASE1":1197,"PHASE2":1199,"PHASE3":1205,"PHASE4":1207,"NA":1209},{"trials":1196,"activeCount":59},[],{"trials":1198,"activeCount":59},[],{"trials":1200,"activeCount":59},[1201],{"nctId":580,"briefTitle":581,"status":67,"phases":1202,"primaryCompletion":583,"completion":584,"start":585,"enrollment":586,"conditions":1203,"interventions":1204},[50],[588,589],[591,577,555,592],{"trials":1206,"activeCount":59},[],{"trials":1208,"activeCount":59},[],{"trials":1210,"activeCount":59},[],{"intervention":592,"totalTrials":85,"cells":1212},{"EARLY_PHASE1":1213,"PHASE1":1215,"PHASE2":1217,"PHASE3":1223,"PHASE4":1225,"NA":1227},{"trials":1214,"activeCount":59},[],{"trials":1216,"activeCount":59},[],{"trials":1218,"activeCount":59},[1219],{"nctId":580,"briefTitle":581,"status":67,"phases":1220,"primaryCompletion":583,"completion":584,"start":585,"enrollment":586,"conditions":1221,"interventions":1222},[50],[588,589],[591,577,555,592],{"trials":1224,"activeCount":59},[],{"trials":1226,"activeCount":59},[],{"trials":1228,"activeCount":59},[],{"intervention":1230,"totalTrials":85,"cells":1231},"catumaxomab, Fluorouracil, leucovorin, oxaliplatin, docetaxel",{"EARLY_PHASE1":1232,"PHASE1":1234,"PHASE2":1236,"PHASE3":1251,"PHASE4":1253,"NA":1255},{"trials":1233,"activeCount":59},[],{"trials":1235,"activeCount":59},[],{"trials":1237,"activeCount":59},[1238],{"nctId":1239,"briefTitle":1240,"status":67,"phases":1241,"primaryCompletion":1242,"completion":1243,"start":1244,"enrollment":125,"conditions":1245,"interventions":1249},"NCT01504256","Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas",[50],"2017-03","2017-07","2011-10",[1246,1247,1248],"Gastric Adenocarcinoma With Peritoneal Carcinomatosis","Siewert Type II Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis","Siewert Type III Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis",[1230,1250],"Fluorouracil, leucovorin, oxaliplatin, docetaxel",{"trials":1252,"activeCount":59},[],{"trials":1254,"activeCount":59},[],{"trials":1256,"activeCount":59},[],{"intervention":1250,"totalTrials":85,"cells":1258},{"EARLY_PHASE1":1259,"PHASE1":1261,"PHASE2":1263,"PHASE3":1269,"PHASE4":1271,"NA":1273},{"trials":1260,"activeCount":59},[],{"trials":1262,"activeCount":59},[],{"trials":1264,"activeCount":59},[1265],{"nctId":1239,"briefTitle":1240,"status":67,"phases":1266,"primaryCompletion":1242,"completion":1243,"start":1244,"enrollment":125,"conditions":1267,"interventions":1268},[50],[1246,1247,1248],[1230,1250],{"trials":1270,"activeCount":59},[],{"trials":1272,"activeCount":59},[],{"trials":1274,"activeCount":59},[],{"intervention":296,"totalTrials":85,"cells":1276},{"EARLY_PHASE1":1277,"PHASE1":1279,"PHASE2":1281,"PHASE3":1287,"PHASE4":1289,"NA":1291},{"trials":1278,"activeCount":59},[],{"trials":1280,"activeCount":59},[],{"trials":1282,"activeCount":59},[1283],{"nctId":288,"briefTitle":289,"status":67,"phases":1284,"primaryCompletion":291,"completion":291,"start":292,"enrollment":293,"conditions":1285,"interventions":1286},[50],[17],[296,279,297,279],{"trials":1288,"activeCount":59},[],{"trials":1290,"activeCount":59},[],{"trials":1292,"activeCount":59},[],{"intervention":297,"totalTrials":85,"cells":1294},{"EARLY_PHASE1":1295,"PHASE1":1297,"PHASE2":1299,"PHASE3":1305,"PHASE4":1307,"NA":1309},{"trials":1296,"activeCount":59},[],{"trials":1298,"activeCount":59},[],{"trials":1300,"activeCount":59},[1301],{"nctId":288,"briefTitle":289,"status":67,"phases":1302,"primaryCompletion":291,"completion":291,"start":292,"enrollment":293,"conditions":1303,"interventions":1304},[50],[17],[296,279,297,279],{"trials":1306,"activeCount":59},[],{"trials":1308,"activeCount":59},[],{"trials":1310,"activeCount":59},[],{"intervention":1312,"totalTrials":85,"cells":1313},"Afatinib",{"EARLY_PHASE1":1314,"PHASE1":1316,"PHASE2":1318,"PHASE3":1329,"PHASE4":1331,"NA":1333},{"trials":1315,"activeCount":59},[],{"trials":1317,"activeCount":59},[],{"trials":1319,"activeCount":59},[1320],{"nctId":1321,"briefTitle":1322,"status":260,"phases":1323,"primaryCompletion":1324,"completion":1324,"start":264,"enrollment":10,"conditions":1325,"interventions":1327},"NCT02488694","Maintaining ERBB Blockade in EGFR-mutated Lung Cancer",[50],"2017-12",[1326],"Non-small-cell Lung Cancer With Somatic EGFR Mutations",[1312,1328],"Pemetrexed",{"trials":1330,"activeCount":59},[],{"trials":1332,"activeCount":59},[],{"trials":1334,"activeCount":59},[],{"intervention":1328,"totalTrials":85,"cells":1336},{"EARLY_PHASE1":1337,"PHASE1":1339,"PHASE2":1341,"PHASE3":1347,"PHASE4":1349,"NA":1351},{"trials":1338,"activeCount":59},[],{"trials":1340,"activeCount":59},[],{"trials":1342,"activeCount":59},[1343],{"nctId":1321,"briefTitle":1322,"status":260,"phases":1344,"primaryCompletion":1324,"completion":1324,"start":264,"enrollment":10,"conditions":1345,"interventions":1346},[50],[1326],[1312,1328],{"trials":1348,"activeCount":59},[],{"trials":1350,"activeCount":59},[],{"trials":1352,"activeCount":59},[],{"intervention":1354,"totalTrials":85,"cells":1355},"OFF",{"EARLY_PHASE1":1356,"PHASE1":1358,"PHASE2":1360,"PHASE3":1373,"PHASE4":1375,"NA":1377},{"trials":1357,"activeCount":59},[],{"trials":1359,"activeCount":59},[],{"trials":1361,"activeCount":59},[1362],{"nctId":1363,"briefTitle":1364,"status":260,"phases":1365,"primaryCompletion":1366,"completion":1366,"start":1367,"enrollment":1368,"conditions":1369,"interventions":1371},"NCT03331640","A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy",[50],"2021-09-13","2018-01-02",67,[1370],"Metastatic Pancreatic Ductal Adenocarcinoma",[1354,1372],"FOLFIRI Protocol",{"trials":1374,"activeCount":59},[],{"trials":1376,"activeCount":59},[],{"trials":1378,"activeCount":59},[],{"intervention":1372,"totalTrials":85,"cells":1380},{"EARLY_PHASE1":1381,"PHASE1":1383,"PHASE2":1385,"PHASE3":1391,"PHASE4":1393,"NA":1395},{"trials":1382,"activeCount":59},[],{"trials":1384,"activeCount":59},[],{"trials":1386,"activeCount":59},[1387],{"nctId":1363,"briefTitle":1364,"status":260,"phases":1388,"primaryCompletion":1366,"completion":1366,"start":1367,"enrollment":1368,"conditions":1389,"interventions":1390},[50],[1370],[1354,1372],{"trials":1392,"activeCount":59},[],{"trials":1394,"activeCount":59},[],{"trials":1396,"activeCount":59},[],{"intervention":178,"totalTrials":85,"cells":1398},{"EARLY_PHASE1":1399,"PHASE1":1401,"PHASE2":1403,"PHASE3":1409,"PHASE4":1411,"NA":1413},{"trials":1400,"activeCount":59},[],{"trials":1402,"activeCount":59},[],{"trials":1404,"activeCount":59},[1405],{"nctId":165,"briefTitle":166,"status":67,"phases":1406,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":1407,"interventions":1408},[50],[22,172,173,174],[176,156,177,178],{"trials":1410,"activeCount":59},[],{"trials":1412,"activeCount":59},[],{"trials":1414,"activeCount":59},[],{"intervention":1416,"totalTrials":85,"cells":1417},"Epirubicin, Cisplatin, Capecitabine, Panitumumab",{"EARLY_PHASE1":1418,"PHASE1":1420,"PHASE2":1422,"PHASE3":1437,"PHASE4":1439,"NA":1441},{"trials":1419,"activeCount":59},[],{"trials":1421,"activeCount":59},[],{"trials":1423,"activeCount":59},[1424],{"nctId":1425,"briefTitle":1426,"status":67,"phases":1427,"primaryCompletion":1428,"completion":1429,"start":1430,"enrollment":1431,"conditions":1432,"interventions":1435},"NCT01234324","ECX + Panitumumab vs. ECX Alone in Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction",[50],"2016-08","2017-08","2010-10",171,[1433,1434],"Stomach Neoplasms","Gastroesophageal Junction Neoplasms",[1416,1436],"Epirubicin, Cisplatin, Capecitabine",{"trials":1438,"activeCount":59},[],{"trials":1440,"activeCount":59},[],{"trials":1442,"activeCount":59},[],{"intervention":1436,"totalTrials":85,"cells":1444},{"EARLY_PHASE1":1445,"PHASE1":1447,"PHASE2":1449,"PHASE3":1455,"PHASE4":1457,"NA":1459},{"trials":1446,"activeCount":59},[],{"trials":1448,"activeCount":59},[],{"trials":1450,"activeCount":59},[1451],{"nctId":1425,"briefTitle":1426,"status":67,"phases":1452,"primaryCompletion":1428,"completion":1429,"start":1430,"enrollment":1431,"conditions":1453,"interventions":1454},[50],[1433,1434],[1416,1436],{"trials":1456,"activeCount":59},[],{"trials":1458,"activeCount":59},[],{"trials":1460,"activeCount":59},[],{"intervention":631,"totalTrials":85,"cells":1462},{"EARLY_PHASE1":1463,"PHASE1":1465,"PHASE2":1467,"PHASE3":1473,"PHASE4":1475,"NA":1477},{"trials":1464,"activeCount":59},[],{"trials":1466,"activeCount":59},[],{"trials":1468,"activeCount":59},[1469],{"nctId":621,"briefTitle":622,"status":260,"phases":1470,"primaryCompletion":624,"completion":625,"start":626,"enrollment":627,"conditions":1471,"interventions":1472},[50],[629],[612,631],{"trials":1474,"activeCount":59},[],{"trials":1476,"activeCount":59},[],{"trials":1478,"activeCount":59},[],{"intervention":784,"totalTrials":85,"cells":1480},{"EARLY_PHASE1":1481,"PHASE1":1483,"PHASE2":1485,"PHASE3":1491,"PHASE4":1493,"NA":1495},{"trials":1482,"activeCount":59},[],{"trials":1484,"activeCount":59},[],{"trials":1486,"activeCount":59},[1487],{"nctId":774,"briefTitle":775,"status":67,"phases":1488,"primaryCompletion":777,"completion":777,"start":778,"enrollment":779,"conditions":1489,"interventions":1490},[50],[781,782],[784,190],{"trials":1492,"activeCount":59},[],{"trials":1494,"activeCount":59},[],{"trials":1496,"activeCount":59},[],{"intervention":1498,"totalTrials":85,"cells":1499},"Avelumab",{"EARLY_PHASE1":1500,"PHASE1":1502,"PHASE2":1504,"PHASE3":1516,"PHASE4":1518,"NA":1520},{"trials":1501,"activeCount":59},[],{"trials":1503,"activeCount":59},[],{"trials":1505,"activeCount":59},[1506],{"nctId":1507,"briefTitle":1508,"status":67,"phases":1509,"primaryCompletion":1510,"completion":1511,"start":1512,"enrollment":1513,"conditions":1514,"interventions":1515},"NCT03174405","Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer - The Phase II AVETUX-CRC Trial.",[50],"2020-07-16","2021-07-16","2017-07-17",43,[17],[1498],{"trials":1517,"activeCount":59},[],{"trials":1519,"activeCount":59},[],{"trials":1521,"activeCount":59},[],{"intervention":1523,"totalTrials":85,"cells":1524},"S-1 de-escalation",{"EARLY_PHASE1":1525,"PHASE1":1527,"PHASE2":1529,"PHASE3":1547,"PHASE4":1549,"NA":1551},{"trials":1526,"activeCount":59},[],{"trials":1528,"activeCount":59},[],{"trials":1530,"activeCount":59},[1531],{"nctId":1532,"briefTitle":1533,"status":67,"phases":1534,"primaryCompletion":1535,"completion":1535,"start":1536,"enrollment":1537,"conditions":1538,"interventions":1545},"NCT02128243","Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer",[50],"2020-10-08","2014-09",242,[1539,1540,1541,1542,1543,1544],"Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction","Gastric Neoplasm","Gastroesophageal Junction Adenocarcinoma","Esophageal Adenocarcinoma","Gastric Adenocarcinoma","Esophageal Neoplasms",[1523,1546],"Chemotherapy by Investigator's choice",{"trials":1548,"activeCount":59},[],{"trials":1550,"activeCount":59},[],{"trials":1552,"activeCount":59},[],{"intervention":1546,"totalTrials":85,"cells":1554},{"EARLY_PHASE1":1555,"PHASE1":1557,"PHASE2":1559,"PHASE3":1565,"PHASE4":1567,"NA":1569},{"trials":1556,"activeCount":59},[],{"trials":1558,"activeCount":59},[],{"trials":1560,"activeCount":59},[1561],{"nctId":1532,"briefTitle":1533,"status":67,"phases":1562,"primaryCompletion":1535,"completion":1535,"start":1536,"enrollment":1537,"conditions":1563,"interventions":1564},[50],[1539,1540,1541,1542,1543,1544],[1523,1546],{"trials":1566,"activeCount":59},[],{"trials":1568,"activeCount":59},[],{"trials":1570,"activeCount":59},[],{"intervention":1572,"totalTrials":85,"cells":1573},"Oxaliplatin, Capecitabine, Panitumumab",{"EARLY_PHASE1":1574,"PHASE1":1576,"PHASE2":1578,"PHASE3":1590,"PHASE4":1592,"NA":1594},{"trials":1575,"activeCount":59},[],{"trials":1577,"activeCount":59},[],{"trials":1579,"activeCount":59},[1580],{"nctId":1581,"briefTitle":1582,"status":260,"phases":1583,"primaryCompletion":597,"completion":1584,"start":1585,"enrollment":1586,"conditions":1587,"interventions":1588},"NCT00950820","Study to Evaluate the Effects of Panitumumab if Combined With Chemotherapy for 2nd Treatment of Colorectal Cancer",[50],"2012-03","2009-09",9,[14],[1572,1589],"Oxaliplatin, Capecitabine",{"trials":1591,"activeCount":59},[],{"trials":1593,"activeCount":59},[],{"trials":1595,"activeCount":59},[],{"intervention":1589,"totalTrials":85,"cells":1597},{"EARLY_PHASE1":1598,"PHASE1":1600,"PHASE2":1602,"PHASE3":1608,"PHASE4":1610,"NA":1612},{"trials":1599,"activeCount":59},[],{"trials":1601,"activeCount":59},[],{"trials":1603,"activeCount":59},[1604],{"nctId":1581,"briefTitle":1582,"status":260,"phases":1605,"primaryCompletion":597,"completion":1584,"start":1585,"enrollment":1586,"conditions":1606,"interventions":1607},[50],[14],[1572,1589],{"trials":1609,"activeCount":59},[],{"trials":1611,"activeCount":59},[],{"trials":1613,"activeCount":59},[],{"intervention":1615,"totalTrials":85,"cells":1616},"Durvalumab and Tremelimumab",{"EARLY_PHASE1":1617,"PHASE1":1619,"PHASE2":1621,"PHASE3":1635,"PHASE4":1637,"NA":1639},{"trials":1618,"activeCount":59},[],{"trials":1620,"activeCount":59},[],{"trials":1622,"activeCount":59},[1623],{"nctId":1624,"briefTitle":1625,"status":67,"phases":1626,"primaryCompletion":1627,"completion":1627,"start":1628,"enrollment":1629,"conditions":1630,"interventions":1633},"NCT03317457","Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma",[50],"2022-08-12","2017-12-15",103,[1631,1632],"Metastatic Adult Soft Tissue Sarcoma","Recurrent Adult Soft Tissue Sarcoma",[1615,1634],"Doxorubicin",{"trials":1636,"activeCount":59},[],{"trials":1638,"activeCount":59},[],{"trials":1640,"activeCount":59},[],{"intervention":1634,"totalTrials":85,"cells":1642},{"EARLY_PHASE1":1643,"PHASE1":1645,"PHASE2":1647,"PHASE3":1653,"PHASE4":1655,"NA":1657},{"trials":1644,"activeCount":59},[],{"trials":1646,"activeCount":59},[],{"trials":1648,"activeCount":59},[1649],{"nctId":1624,"briefTitle":1625,"status":67,"phases":1650,"primaryCompletion":1627,"completion":1627,"start":1628,"enrollment":1629,"conditions":1651,"interventions":1652},[50],[1631,1632],[1615,1634],{"trials":1654,"activeCount":59},[],{"trials":1656,"activeCount":59},[],{"trials":1658,"activeCount":59},[],{"intervention":1660,"totalTrials":85,"cells":1661},"FOLFOXIRI + Panitumumab",{"EARLY_PHASE1":1662,"PHASE1":1664,"PHASE2":1666,"PHASE3":1678,"PHASE4":1680,"NA":1682},{"trials":1663,"activeCount":59},[],{"trials":1665,"activeCount":59},[],{"trials":1667,"activeCount":59},[1668],{"nctId":1669,"briefTitle":1670,"status":67,"phases":1671,"primaryCompletion":1672,"completion":1673,"start":1674,"enrollment":899,"conditions":1675,"interventions":1676},"NCT01328171","FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)",[50],"2017-06","2022-01","2011-04",[17],[1660,1677],"FOLFOXIRI",{"trials":1679,"activeCount":59},[],{"trials":1681,"activeCount":59},[],{"trials":1683,"activeCount":59},[],{"intervention":1677,"totalTrials":85,"cells":1685},{"EARLY_PHASE1":1686,"PHASE1":1688,"PHASE2":1690,"PHASE3":1696,"PHASE4":1698,"NA":1700},{"trials":1687,"activeCount":59},[],{"trials":1689,"activeCount":59},[],{"trials":1691,"activeCount":59},[1692],{"nctId":1669,"briefTitle":1670,"status":67,"phases":1693,"primaryCompletion":1672,"completion":1673,"start":1674,"enrollment":899,"conditions":1694,"interventions":1695},[50],[17],[1660,1677],{"trials":1697,"activeCount":59},[],{"trials":1699,"activeCount":59},[],{"trials":1701,"activeCount":59},[],{"intervention":1703,"totalTrials":85,"cells":1704},"S-1",{"EARLY_PHASE1":1705,"PHASE1":1707,"PHASE2":1709,"PHASE3":1722,"PHASE4":1724,"NA":1726},{"trials":1706,"activeCount":59},[],{"trials":1708,"activeCount":59},[],{"trials":1710,"activeCount":59},[1711],{"nctId":1712,"briefTitle":1713,"status":67,"phases":1714,"primaryCompletion":1715,"completion":1716,"start":1717,"enrollment":639,"conditions":1718,"interventions":1721},"NCT02564367","Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction",[49,50],"2019-03-01","2020-03-06","2015-10-06",[1719,1720],"Adenocarcinoma,Stomach","Adenocarcinoma, Esophagogastric Junction",[1703],{"trials":1723,"activeCount":59},[],{"trials":1725,"activeCount":59},[],{"trials":1727,"activeCount":59},[],{"intervention":1729,"totalTrials":85,"cells":1730},"Everolimus",{"EARLY_PHASE1":1731,"PHASE1":1733,"PHASE2":1735,"PHASE3":1750,"PHASE4":1752,"NA":1754},{"trials":1732,"activeCount":59},[],{"trials":1734,"activeCount":59},[],{"trials":1736,"activeCount":59},[1737],{"nctId":1738,"briefTitle":1739,"status":67,"phases":1740,"primaryCompletion":1741,"completion":1741,"start":425,"enrollment":1742,"conditions":1743,"interventions":1749},"NCT02113800","Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma \u002F Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study",[50],"2020-04",40,[1744,1745,1746,1747,1748],"Poorly Differentiated Malignant Neuroendocrine Carcinoma","Neuroendocrine Carcinoma, Grade 3","Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3","Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma] That Switched to G3","Neuroendocrine Tumor, Grade 3 and Disease Progression as Measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1.)",[1729],{"trials":1751,"activeCount":59},[],{"trials":1753,"activeCount":59},[],{"trials":1755,"activeCount":59},[],{"intervention":1757,"totalTrials":85,"cells":1758},"nab-paclitaxel and gemcitabine",{"EARLY_PHASE1":1759,"PHASE1":1761,"PHASE2":1763,"PHASE3":1776,"PHASE4":1778,"NA":1780},{"trials":1760,"activeCount":59},[],{"trials":1762,"activeCount":59},[],{"trials":1764,"activeCount":59},[1765],{"nctId":1766,"briefTitle":1767,"status":67,"phases":1768,"primaryCompletion":1769,"completion":1770,"start":529,"enrollment":1771,"conditions":1772,"interventions":1774},"NCT02564146","First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine",[50],"2022-03","2022-05",325,[24,1773],"Adenocarcinoma of the Pancreas",[1757,1775],"gemcitabine mono and nab-paclitaxel and gemcitabine",{"trials":1777,"activeCount":59},[],{"trials":1779,"activeCount":59},[],{"trials":1781,"activeCount":59},[],{"intervention":1775,"totalTrials":85,"cells":1783},{"EARLY_PHASE1":1784,"PHASE1":1786,"PHASE2":1788,"PHASE3":1794,"PHASE4":1796,"NA":1798},{"trials":1785,"activeCount":59},[],{"trials":1787,"activeCount":59},[],{"trials":1789,"activeCount":59},[1790],{"nctId":1766,"briefTitle":1767,"status":67,"phases":1791,"primaryCompletion":1769,"completion":1770,"start":529,"enrollment":1771,"conditions":1792,"interventions":1793},[50],[24,1773],[1757,1775],{"trials":1795,"activeCount":59},[],{"trials":1797,"activeCount":59},[],{"trials":1799,"activeCount":59},[],{"intervention":1801,"totalTrials":85,"cells":1802},"nintedanib-nivolumab combination therapy",{"EARLY_PHASE1":1803,"PHASE1":1805,"PHASE2":1807,"PHASE3":1820,"PHASE4":1822,"NA":1824},{"trials":1804,"activeCount":59},[],{"trials":1806,"activeCount":59},[],{"trials":1808,"activeCount":59},[1809],{"nctId":1810,"briefTitle":1811,"status":67,"phases":1812,"primaryCompletion":1813,"completion":1814,"start":1815,"enrollment":1816,"conditions":1817,"interventions":1819},"NCT04046614","Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology",[49,50],"2023-05-23","2023-09-15","2018-05-25",56,[1818],"Adenocarcinoma of the Lung",[1801],{"trials":1821,"activeCount":59},[],{"trials":1823,"activeCount":59},[],{"trials":1825,"activeCount":59},[],{"intervention":1827,"totalTrials":85,"cells":1828},"combination regimen tremelimumab \u002Fdurvalumab",{"EARLY_PHASE1":1829,"PHASE1":1831,"PHASE2":1833,"PHASE3":1846,"PHASE4":1848,"NA":1850},{"trials":1830,"activeCount":59},[],{"trials":1832,"activeCount":59},[],{"trials":1834,"activeCount":59},[1835],{"nctId":1836,"briefTitle":1837,"status":1838,"phases":1839,"primaryCompletion":1840,"completion":1840,"start":1841,"enrollment":59,"conditions":1842,"interventions":1844},"NCT05383001","Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)","WITHDRAWN",[50],"2026-05","2022-05-20",[1843],"NSCLC Stage IV",[1827,1845],"platinum-based chemotherapy",{"trials":1847,"activeCount":59},[],{"trials":1849,"activeCount":59},[],{"trials":1851,"activeCount":59},[],{"intervention":1845,"totalTrials":85,"cells":1853},{"EARLY_PHASE1":1854,"PHASE1":1856,"PHASE2":1858,"PHASE3":1864,"PHASE4":1866,"NA":1868},{"trials":1855,"activeCount":59},[],{"trials":1857,"activeCount":59},[],{"trials":1859,"activeCount":59},[1860],{"nctId":1836,"briefTitle":1837,"status":1838,"phases":1861,"primaryCompletion":1840,"completion":1840,"start":1841,"enrollment":59,"conditions":1862,"interventions":1863},[50],[1843],[1827,1845],{"trials":1865,"activeCount":59},[],{"trials":1867,"activeCount":59},[],{"trials":1869,"activeCount":59},[],{"intervention":192,"totalTrials":85,"cells":1871},{"EARLY_PHASE1":1872,"PHASE1":1874,"PHASE2":1876,"PHASE3":1882,"PHASE4":1884,"NA":1886},{"trials":1873,"activeCount":59},[],{"trials":1875,"activeCount":59},[],{"trials":1877,"activeCount":59},[1878],{"nctId":180,"briefTitle":181,"status":67,"phases":1879,"primaryCompletion":183,"completion":183,"start":184,"enrollment":185,"conditions":1880,"interventions":1881},[50],[187,26,188,28,30],[176,190,156,191,192],{"trials":1883,"activeCount":59},[],{"trials":1885,"activeCount":59},[],{"trials":1887,"activeCount":59},[],{"intervention":602,"totalTrials":85,"cells":1889},{"EARLY_PHASE1":1890,"PHASE1":1892,"PHASE2":1894,"PHASE3":1900,"PHASE4":1902,"NA":1904},{"trials":1891,"activeCount":59},[],{"trials":1893,"activeCount":59},[],{"trials":1895,"activeCount":59},[1896],{"nctId":594,"briefTitle":595,"status":260,"phases":1897,"primaryCompletion":597,"completion":598,"start":599,"enrollment":499,"conditions":1898,"interventions":1899},[50],[14],[602,603,555,604],{"trials":1901,"activeCount":59},[],{"trials":1903,"activeCount":59},[],{"trials":1905,"activeCount":59},[],{"intervention":603,"totalTrials":85,"cells":1907},{"EARLY_PHASE1":1908,"PHASE1":1910,"PHASE2":1912,"PHASE3":1918,"PHASE4":1920,"NA":1922},{"trials":1909,"activeCount":59},[],{"trials":1911,"activeCount":59},[],{"trials":1913,"activeCount":59},[1914],{"nctId":594,"briefTitle":595,"status":260,"phases":1915,"primaryCompletion":597,"completion":598,"start":599,"enrollment":499,"conditions":1916,"interventions":1917},[50],[14],[602,603,555,604],{"trials":1919,"activeCount":59},[],{"trials":1921,"activeCount":59},[],{"trials":1923,"activeCount":59},[],{"intervention":604,"totalTrials":85,"cells":1925},{"EARLY_PHASE1":1926,"PHASE1":1928,"PHASE2":1930,"PHASE3":1936,"PHASE4":1938,"NA":1940},{"trials":1927,"activeCount":59},[],{"trials":1929,"activeCount":59},[],{"trials":1931,"activeCount":59},[1932],{"nctId":594,"briefTitle":595,"status":260,"phases":1933,"primaryCompletion":597,"completion":598,"start":599,"enrollment":499,"conditions":1934,"interventions":1935},[50],[14],[602,603,555,604],{"trials":1937,"activeCount":59},[],{"trials":1939,"activeCount":59},[],{"trials":1941,"activeCount":59},[],{"intervention":1943,"totalTrials":85,"cells":1944},"Gem\u002Fnab-Pac",{"EARLY_PHASE1":1945,"PHASE1":1947,"PHASE2":1949,"PHASE3":1961,"PHASE4":1963,"NA":1965},{"trials":1946,"activeCount":59},[],{"trials":1948,"activeCount":59},[],{"trials":1950,"activeCount":59},[1951],{"nctId":1952,"briefTitle":1953,"status":67,"phases":1954,"primaryCompletion":1715,"completion":1955,"start":1956,"enrollment":1957,"conditions":1958,"interventions":1959},"NCT02125136","Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer",[50],"2020-02-19","2014-11",168,[1058],[1943,1960],"FOLFIFINOX",{"trials":1962,"activeCount":59},[],{"trials":1964,"activeCount":59},[],{"trials":1966,"activeCount":59},[],{"intervention":1960,"totalTrials":85,"cells":1968},{"EARLY_PHASE1":1969,"PHASE1":1971,"PHASE2":1973,"PHASE3":1979,"PHASE4":1981,"NA":1983},{"trials":1970,"activeCount":59},[],{"trials":1972,"activeCount":59},[],{"trials":1974,"activeCount":59},[1975],{"nctId":1952,"briefTitle":1953,"status":67,"phases":1976,"primaryCompletion":1715,"completion":1955,"start":1956,"enrollment":1957,"conditions":1977,"interventions":1978},[50],[1058],[1943,1960],{"trials":1980,"activeCount":59},[],{"trials":1982,"activeCount":59},[],{"trials":1984,"activeCount":59},[],{"intervention":1986,"totalTrials":85,"cells":1987},"TAS 102",{"EARLY_PHASE1":1988,"PHASE1":1990,"PHASE2":2004,"PHASE3":2006,"PHASE4":2008,"NA":2010},{"trials":1989,"activeCount":59},[],{"trials":1991,"activeCount":59},[1992],{"nctId":1993,"briefTitle":1994,"status":67,"phases":1995,"primaryCompletion":1996,"completion":1997,"start":1998,"enrollment":1999,"conditions":2000,"interventions":2002},"NCT03305913","Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy",[49],"2018-10-31","2019-04-26","2017-07-31",12,[2001],"Pretreated Metastatic Colorectal Cancer",[1986,2003],"Regorafenib",{"trials":2005,"activeCount":59},[],{"trials":2007,"activeCount":59},[],{"trials":2009,"activeCount":59},[],{"trials":2011,"activeCount":59},[],{"intervention":2003,"totalTrials":85,"cells":2013},{"EARLY_PHASE1":2014,"PHASE1":2016,"PHASE2":2022,"PHASE3":2024,"PHASE4":2026,"NA":2028},{"trials":2015,"activeCount":59},[],{"trials":2017,"activeCount":59},[2018],{"nctId":1993,"briefTitle":1994,"status":67,"phases":2019,"primaryCompletion":1996,"completion":1997,"start":1998,"enrollment":1999,"conditions":2020,"interventions":2021},[49],[2001],[1986,2003],{"trials":2023,"activeCount":59},[],{"trials":2025,"activeCount":59},[],{"trials":2027,"activeCount":59},[],{"trials":2029,"activeCount":59},[]]